James L. Januzzi, MD, FACC
Cardiologist
Harvard Medical School

Printed as of 11/6/2026

Disclosures

Personal Commercial (16)

Company Name	Relationship Category	Compensation Level	*Topic Area(s)*
Self			
Abbott Laboratories	Research/Research Grants ‡ *Pilot Study*	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Abbott Laboratories	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
AbbVie, Inc.	Data Safety Monitoring Board	Significant (>= $5,000)	*General Cardiology*
Abiomed	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
AstraZeneca Pharmaceuticals	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Bayer Healthcare Pharmaceuticals	Data Safety Monitoring Board	Modest (< $5,000)	*General Cardiology*
Beckman Coulter	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Eli Lilly and Company	Consultant Fees/Honoraria	Modest (< $5,000)	*Prevention*
Imbria	Consultant Fees/Honoraria	Significant (>= $5,000)	*Stable Ischemic Heart Disease*
Jana Care	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Medtronic	Research/Research Grants	Modest (< $5,000)	*Valvular Heart Disease*
Novartis	Research/Research Grants	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies*
Prevencio	Consultant Fees/Honoraria	Significant (>= $5,000)	*General Cardiology*
Roche Diagnostics	Consultant Fees/Honoraria	Significant (>= $5,000)	*Heart Failure and Cardiomyopathies* *General Cardiology*
Siemens	Consultant Fees/Honoraria	Modest (< $5,000)	*Heart Failure and Cardiomyopathies*
Takeda Pharmaceuticals North America, Inc	Data Safety Monitoring Board	Significant (>= $5,000)	*General Cardiology*

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 11/8/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

Confidentiality, Disclosure and Assignment Agreement | Signed on 11/8/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 11/8/2025
URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 11/8/2025

ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.